Cerevel Therapeutics LLC has described muscarinic M4 receptor agonists reported to be useful for the treatment of pain, sleep disorder, schizophrenia, substance abuse and dependence, drug-induced dyskinesia, Alzheimer’s disease and Parkinson’s disease.
Psychiatric indications, such as depression, schizophrenia and bipolar disorder, share a common feature of elevated expression of pro-inflammatory markers in the periphery and/or central nervous system. Based on this, it is believed that combined immuno- and neuromodulatory activities of phosphodiesterase 4 (PDE4) inhibitors may represent a promising new therapeutic strategy for various psychiatric indications.
Researchers from Cerevel Therapeutics LLC presented data from a study that aimed to evaluate preclinical antipsychotic properties of M4 agonism while minimizing off-target side effects using novel muscarinic acetylcholine M4 receptor full and partial agonists, CV-0000042 (CVL-042) and CV-0000071, respectively.
